$ATYR
aTyr Pharma Inc

2019 Q1 Form 10-Q Financial Statement

#000156459019019133 Filed on May 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.530M $4.070M
YoY Change -37.84% 1.5%
% of Gross Profit
Research & Development $3.350M $6.150M
YoY Change -45.53% -33.18%
% of Gross Profit
Depreciation & Amortization $167.0K $184.0K
YoY Change -9.24% -18.58%
% of Gross Profit
Operating Expenses $5.877M $10.22M
YoY Change -42.5% -22.64%
Operating Profit -$5.877M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$260.0K -$447.0K
YoY Change -41.83% 130.41%
Pretax Income -$6.140M -$10.67M
YoY Change -42.46% -20.43%
Income Tax
% Of Pretax Income
Net Earnings -$6.137M -$10.67M
YoY Change -42.47% -20.43%
Net Earnings / Revenue
Basic Earnings Per Share -$2.54
Diluted Earnings Per Share -$2.54 -$5.009M
COMMON SHARES
Basic Shares Outstanding 2.419M
Diluted Shares Outstanding 2.419M

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.00M $74.10M
YoY Change -41.97% 19.64%
Cash & Equivalents $13.00M $21.94M
Short-Term Investments $30.10M $52.20M
Other Short-Term Assets $1.100M $1.900M
YoY Change -42.11% 5.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.70M $76.00M
YoY Change -41.18% 19.12%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000M $2.374M
YoY Change 110.61% 48.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $90.00K
YoY Change 122.22% -70.0%
Total Long-Term Assets $5.200M $2.470M
YoY Change 110.53% 30.0%
TOTAL ASSETS
Total Short-Term Assets $44.70M $76.00M
Total Long-Term Assets $5.200M $2.470M
Total Assets $49.90M $78.47M
YoY Change -36.41% 19.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $800.0K $1.462M
YoY Change -45.28% 21.83%
Accrued Expenses $1.900M $2.533M
YoY Change -24.99% -39.69%
Deferred Revenue $630.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.800M $7.027M
YoY Change 11.0% 542.32%
Total Short-Term Liabilities $11.20M $11.02M
YoY Change 1.61% 68.3%
LONG-TERM LIABILITIES
Long-Term Debt $6.400M $12.95M
YoY Change -50.58% 52.71%
Other Long-Term Liabilities $2.800M
YoY Change
Total Long-Term Liabilities $9.200M $12.95M
YoY Change -28.96% 52.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.20M $11.02M
Total Long-Term Liabilities $9.200M $12.95M
Total Liabilities $20.40M $23.97M
YoY Change -14.9% 59.5%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.49M $54.50M
YoY Change
Total Liabilities & Shareholders Equity $49.90M $78.50M
YoY Change -36.43% 19.42%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$6.137M -$10.67M
YoY Change -42.47% -20.43%
Depreciation, Depletion And Amortization $167.0K $184.0K
YoY Change -9.24% -18.58%
Cash From Operating Activities -$6.023M -$10.58M
YoY Change -43.06% -23.85%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $498.0K
YoY Change -97.99% 90.08%
Acquisitions
YoY Change
Other Investing Activities -$3.350M $11.91M
YoY Change -128.13% 155.58%
Cash From Investing Activities -$3.355M $11.41M
YoY Change -129.39% 159.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.000K
YoY Change 700.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -619.0K 8.000K
YoY Change -7837.5%
NET CHANGE
Cash From Operating Activities -6.023M -10.58M
Cash From Investing Activities -3.355M 11.41M
Cash From Financing Activities -619.0K 8.000K
Net Change In Cash -9.997M 845.0K
YoY Change -1283.08% -108.9%
FREE CASH FLOW
Cash From Operating Activities -$6.023M -$10.58M
Capital Expenditures $10.00K $498.0K
Free Cash Flow -$6.033M -$11.08M
YoY Change -45.53% -21.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 life Collaboration Receivable Current
CollaborationReceivableCurrent
630000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3323000
CY2019Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
630000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
681000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2815000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-6137000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
64245000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
571000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-260000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-447000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6137000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-10667000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6117000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10683000
CY2019Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1381000
CY2018Q1 life Issuance Of Common Stock Upon Exercise Of Options And Release Of Restricted Stock Units
IssuanceOfCommonStockUponExerciseOfOptionsAndReleaseOfRestrictedStockUnits
8000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
928000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-10667000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
184000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
571000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
928000
CY2019Q1 us-gaap Accretion Expense
AccretionExpense
201000
CY2018Q1 us-gaap Accretion Expense
AccretionExpense
81000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
106000
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
64000
CY2019Q1 life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
169000
CY2019Q1 life Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
630000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-97000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
40000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-985000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-999000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
630000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6023000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10577000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
498000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
13995000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
7988000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
10650000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
19900000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3355000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11414000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8000
CY2019Q1 life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
1381000
CY2019Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-619000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9997000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
845000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21091000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21936000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p>
CY2018Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
With the lease amendment, we do not have an option to extend the lease
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
732000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20596998
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23755434
CY2019Q1 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Issuable in three separate tranches (the Term Loans), $10.0 million of which was funded in November 2016, $5.0 million of which was funded in June 2017 and $5.0 million of which was funded in December 2017.
CY2019Q1 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3500000
CY2019Q1 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
43000000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3500000
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0960
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2017Q2 life Lease Facility
LeaseFacility
24494
CY2018Q3 life Lease Facility
LeaseFacility
20508
CY2018Q3 life Lease Expiration Term
LeaseExpirationTerm
2023-05
CY2018Q3 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1002000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1031000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1062000
CY2019Q1 life Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
403000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
734000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3496000
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23897681
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4990674
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
856493
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.38
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.77

Files In Submission

Name View Source Status
0001564590-19-019133-index-headers.html Edgar Link pending
0001564590-19-019133-index.html Edgar Link pending
0001564590-19-019133.txt Edgar Link pending
0001564590-19-019133-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gtizxco2xprd000001.jpg Edgar Link pending
gtizxco2xprd000002.jpg Edgar Link pending
life-10q_20190331.htm Edgar Link pending
life-20190331.xml Edgar Link completed
life-20190331.xsd Edgar Link pending
life-20190331_cal.xml Edgar Link unprocessable
life-20190331_def.xml Edgar Link unprocessable
life-20190331_lab.xml Edgar Link unprocessable
life-20190331_pre.xml Edgar Link unprocessable
life-ex102_52.htm Edgar Link pending
life-ex311_7.htm Edgar Link pending
life-ex312_10.htm Edgar Link pending
life-ex321_9.htm Edgar Link pending
life-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending